New Classification and Treatment Strategies in Antiphospholipid Syndrome

In this MEDtalk, Professor Ricard Cervera, Head of the Department of Autoimmune Diseases at Hospital Clínic, Barcelona, outlines the recently endorsed classification criteria for antiphospholipid syndrome (APS). He explains how these criteria enhance research precision by incorporating weighted clinical and laboratory domains, including new cardiac and microvascular parameters. Professor Cervera also reviews current evidence-based treatment approaches for catastrophic APS, highlighting the impact of triple therapy and emerging roles for complement and B-cell–targeted therapies.